SCHEMBL3534672

SCHEMBL3534672

CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)CCN4C(=O)OC(C)(C)C)csc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 9/20 0.59
AURKB Q96GD4 7/20 0.59
KDR P35968 7/20 0.59
MAP4K4 O95819 6/20 0.59
FYN P06241 6/20 0.59
CSF1R P07333 6/20 0.59
FGFR1 P11362 6/20 0.59
FLT1 P17948 6/20 0.59
FLT3 P36888 6/20 0.59
NEK2 P51955 6/20 0.59
MAP4K2 Q12851 6/20 0.59
BTK Q06187 6/20 0.59
PLK4 O00444 5/20 0.59
LYN P07948 5/20 0.59
SRC P12931 5/20 0.59
FGFR3 P22607 5/20 0.59
RPS6KB1 P23443 5/20 0.59
FLT4 P35916 5/20 0.59
CSNK1D P48730 5/20 0.59
BLK P51451 5/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534670 1.00 LCK (0.59) LCKAURKBKDRMAP4K4FYN
SCHEMBL14033124 0.81 EIF2AK3 (0.70) LCKAURKBKDRBTKEIF2AK3
SCHEMBL869335 0.79 EIF2AK3 (0.66) LCKAURKBKDRMAP4K4CSF1R
SCHEMBL3528888 0.77 LCK (0.66) LCKAURKBKDRMAP4K4FYN
SCHEMBL3528886 0.77 LCK (0.66) LCKAURKBKDRMAP4K4FYN
SCHEMBL3533711 0.76 KDR (0.71) LCKAURKBKDRMAP4K4FYN
SCHEMBL3533708 0.76 KDR (0.71) LCKAURKBKDRMAP4K4FYN
SCHEMBL3534440 0.76 LCK (0.68) LCKAURKBKDRMAP4K4FYN
SCHEMBL3534445 0.76 LCK (0.68) LCKAURKBKDRMAP4K4FYN
SCHEMBL3536072 0.75 KDR (0.72) LCKAURKBKDRMAP4K4FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK LCK 3/4885AURKB 171/4885KDR 494/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK LCK 3/4885AURKB 171/4885KDR 494/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK LCK 3/4885AURKB 171/4885KDR 494/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK LCK 3/4885AURKB 171/4885KDR 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.